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A Combined Carcinogen Bioassay Utilizing
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Papilloma Protocols
by Merrel Robinson,* Richard J. BulI,t Gary L. Knutsen,t
Robert P. Shields,** and Judy Stober*
Totest thefeasibility ofemploying acombined lungadenoma/skinpapillomaassayforbroaderdetection
of chemical carcinogenesis than that realized with either bioassay done separately, four strains of mice,
SENCAR, BALB/c, A/J, andICR-Swiss, wereadministeredcarcinogenseitherbytheoralorintraperitoneal
(IP) routes. The carcinogens administered were ethyl carbamate (EC), benzo(a)pyrene [B(a)P], N-[4-(5-
nitro-2-furyl)thiazolyl]formamide (FANFT), and acrylamide (ACR). Starting 2 weeks later, 1 to 5 ,g
(depending on strain) of12-O-tetradecanoylphorbol-13-acetate (TPA) in 0.2 mL acetone/mouse was applied
three times weekly to the shaved back for 20 weeks. All strains displayed increases in the yield of lung
adenomas in response to EC at 32 weeks. B(a)P increased lung adenomas in only the SENCAR and A/J
strain. Only the SENCAR and ICR-Swiss mice gave positive responses in the skin. In the SENCAR mice,
positive response was seen with all four chemicals, however, FANFT gave an inconsistent response. The
ICR-Swiss mice responded with an increased skin papilloma yield only to EC. In a separate experiment
involving only SENCAR mice, animals were treated with a single oral dose ofdiethylnitrosamine (DEN)
followed by triweekly application of 1.0 ,g TPA. This treatment resulted in 51/57 animals developing lung
adenomas vs. 5/57 in the control animals. No treatment-related skin tumors resulted with DEN. Histo-
pathologically confirmed lesions indicate that the spectrum ofchemicals detected in the SENCAR mouse
may be broadened using a combined bioassay that examines both lung and skin responses.
Introduction
The mouse skin papilloma assay as described by Ber-
enblum et al. (1,2) and Boutwell et al. (3,4) and mouse
lung adenoma assay as described by Shimkin et al. (5)
and Stoner et al. (6) are two carcinogen test systems
that have been suggested by Bull et al. (7) for Tier 2
confirmation testing of putatively carcinogenic chemi-
cals or mixtures. Although several different strains of
mice have been used for these tests, the SENCAR
mouse is the most sensitive model in the skin papilloma
assay (8), and the A/J strain is the most susceptible
model for lung adenomas (9). In an attempt to offset
the occurrence offalsenegativesinthesetwocarcinogen
test models, our laboratory is testing the feasibility of
using a single mouse model for conducting a combined
assay for skin papillomas and lung adenomas. To that
end, we have studied skin and lung responses of four
different strains of mice to the administration of four
different chemical carcinogens. One strain (ICR-Swiss)
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was examined because it is known to be sensitive to the
induction ofboth lung adenomas and skin papillomas by
chemical carcinogens (9,10). The BALB/c strain was
included as a strain that was recognized to be relatively
insensitive to skin tumor initiation and lung tumor de-
velopment. All four strains were compared grossly for
their carcinogenic response to benzo(a)pyrene[B(a)P],
ethyl carbamate (EC), acrylamide (AC). N-[4-(5-nitro-
2-furyl)thiazolyl]formamide (FANFT). Diethylnitrosa-
mine (DEN) was also tested in the SENCAR mouse.
These findings were more critically assessed by histo-
pathological examination.
Methods
Chemicals
B(a)P was obtained from Aldrich (Milwaukee, WI),
DEN from Eastman Kodak Co. (Rochester, NY),
FANFT from Saber Labs (Morton Grove, IL), and EC
from MCB (Gibbstown, NJ). B(a)P was designated 98%
pure, and the other chemicals were of reagent grade
classification; all were used as received. ACR was pur-
chased from Eastman Kodak and found to be more than
99% pure by GC-MS analysis (11). 12-0-tetradecanoyl-ROBINSON ET AL.
phenol-13-acetate (TPA) was purchased from Chemical
Carcinogenesis (Eden Prairie, MN).
Biological Testing
Only female mice were used forthis study. The SEN-
CAR and ICR-Swiss were obtained from Harlan Spra-
gue-Dawley, Inc. (Indianapolis, IN), BALB/cmice from
Charles River (Wilmington, MA), and A/J mice from
Jackson Labs (Bar Harbor, ME). Three experiments
were conducted. In experiment 1, DEN wastested only
in the SENCAR mouse. A single dose of50 mg/kg was
administered by oral intubation in a 10% Emulphor (po-
lyoxygenated vegetable oil) solution. There were 60 an-
imals in the group with 40 receivingTPA (1.0 ,ug, three
times weekly for 20 weeks) and 20 receiving acetone as
indicated above. The skin tumors were charted for one
year in this group, and lung adenoma determinations
were made following sacrifice at that point. In experi-
ment 2 only SENCAR mice were tested, and B(a)P was
administered in a single dose of 100 mg/kg, rather than
the 50 mg/kg as used in experiment 3. All other aspects
of the protocol are the same as described below for
experiment 3. In experiment 3 a single dose ofEC (300
mg/kg), B(a)P (50 mg/kg), or FANFT (500 mg/kg) was
administered intraperitoneal (I.P.) to 60 mice of each
ofthe four strains. Two days following this dose, 40 of
the 60 mice in each group received 1.0 ,ig (SENCAR),
2.5 ,ug (A/J and ICR-Swiss), or 5.0 jig (BALB/c) TPA
in 0.2 mL acetone applied topically three times weekly
for 20 weeks. The remaining 20 mice received only ace-
tone for the same schedule and duration of treatment.
The appearance and regression of skin tumors were
charted weekly. Only tumors of 1 mm or greater and
persisting for a least three observations were included
in the cumulative count. The animals were sacrificed at
36 weeks of age, and gross lung adenoma counts were
determined according to the method reported by
Shimkin (5). Briefly described, the method involves ex-
cising the lungs at time of sacrifice and fixing them in
a 10% formalin solution. Three to four days later, the
lungs were examined under a Spencer dissecting micro-
scope (x 10) and the number of surface adenomas was
counted. Microscopic examinations were done on all
grossly observed nodules, and final counts were ad-
justed to include only confirmed adenomas.
In each study, papillomas were included in the tumor
count only ifthey were observed for three consecutive
weeks. At the time of sacrifice, all gross lesions were
noted and fixed in 10% buffered formalin forsubsequent
histopathological evaluation. To further validate the
gross lung tumor counts in experiments 2 and 3, all
questionable lung lesions were examined microscopi-
cally and totalcounts were adjusted to reflect confirmed
adenomas. Skin lesions present at sacrifice were also
examinedmicroscopically (findingsnotreported). Tode-
termine the statistical significance ofthe data, the chi-
square was used for experiment 1. For experiments 2
and 3, lung adenoma data were analyzed by Fisher's
Table 1. Results of combined lung adenoma and skin papillomas
assays in SENCAR mouse following oral treatment with
diethylnitrosamine.
Animals with tumors, %
Chemical and dosea Lung adenoma Papilloma
Diethylnitrosamine 50 mg/kg 85b 13
Vehicle (Emulphor 10%) 8 23
aChemical was administered in single injection in Emulphor to 60
animals. Two weeks later applications of TPA were made at 1.0 ,ug
in 0.2 mL acetone three times weekly for 20 weeks to shaved backs
of 40 animals. Results are reported as percentage of animals having
tumors after 40 weeks on study. Lung adenoma counts include the
total of60 animals inthe group (40 receivingTPA-33had adenomas;
and 20 not receiving TPA- 18 had adenomas), whereas data on skin
papillomas are derived only from the 40 animals receiving TPA pro-
motion.
bSignificantly different from control value (p < 0.0001) as deter-
mined by chi-square test.
exact test and skin papillomas data by the Gehan-Wil-
coxon-type multiple comparison test (12).
Results
In the first experiment (Table 1), treatment with
DEN resulted in a significant increase (p < 0.0001) in
the number of mice bearing lung tumors compared to
the vehicle controlgroup. The Shimkinmethodofcount-
ing lung adenomas was not used in this experiment,
and, therefore, the total adenomacount is notavailable.
Of the animals treated with DEN, only 13% had skin
papillomas, whereas in the control group, 23% of the
animals developed papillomas. This high rate may be
partially attributable to the longer time to sacrifice in
this experiment, but it still represents a higher rate
than average for historical controls for SENCAR mice
held for the same period in our laboratory (11%). This
laboratory has recently started using a 2% Emulphor
vehicle for oral administration oftest materials requir-
ing an organic solvent, in an attempt to alleviate this
problem. These datasuggestthat SENCAR mice might
beappropriatelyusedinacombined skinandlungassay.
The skin and lung responses of the four strains of
mice following treatment with three known carcinogens
are presented in Table 2. The relative sensitivity ofthe
different mouse strains to EC-induced lung adenomas
was A/J > SENCAR = ICR > BALB/c, with the last
strain displaying a very marginal response. ACR also
induced lung tumors, but the sensitivity of the SEN-
CAR and A/J mice was approximately equivalent. A
very marginal response was seen in ICR mice and no
lungtumors were observed in BALB/c mice. B(a)P pro-
duced anincreasedyieldoflungtumorsinthe SENCAR
(p < 0.05) and A/J (p < 0.05) strains. A slight increase
in lung adenomas was seen in ICR-Swiss mice with
exposure to B(a)P, but this increase was not significant.
FANFT was negative for lung adenomas in all strains.
Both experiments 2 and 3 produced similar lung ade-
noma yields in the SENCAR mouse.
Only the SENCAR skin responded positively to car-
cinogen administration (Table 2). The four chemicals
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Table 2. Comparison of strain sensitivities to lung adenoma and skin papilloma induction in a combined protocol following
intraperitoneal treatment with known animal carcinogens.8
Dose, Expt. 2, Expt. 3
Tumor Chemical mg/kg SENCAR SENCAR BALB/c A/J ICR
Lung adenoma Ethyl carbamate 300 1.38b* 1.53* 0.14 4.92* 1.26*
Benzo(a)pyrene 50C 0.37 0.49t 0.02 0.56t 0.16
FANFT 500 0.07 0.07 0.11 0.08 0.09
Acrylamide 50 0.38 0.42t 0.05 0.43 0.10
Emulphor (vehicle) 0.29 0.14 0.03 0.16 0.05
Water 0.22 0.04 0.03 0.11 0.00
Skin papilloma Ethyl carbamate 300 1.68* 0.75t 0.08 0 0.68
Benzo(a)pyrene 50c 0.70c 0.23 0 0 0.03
FANFT 500 0.43 0.15 0 0 0.20
Acrylamide 50 0.25t 0.38* 0 0 0.25
Emulphor (vehicle) 0.18 0.08 0.05 0 0.08
Water (vehicle) 0.08 0.05 0 0 0.13
aThe indicated carcinogens were administered in a single IP injection in an Emulphor or water (acrylamide) vehicle to 60 animals. Two
weeks later applications of TPA were started. TPA doses varied for different strains and were applied in 0.2 mL acetone 3 times weekly for
20 weeks to the shaved backs of40 animals in each group. SENCAR mice received 1.0 Fg, BALB/c 5.0 jig, and both A/J and ICR-Swiss mice
2.5 ,ug of TPA per topical application 3 times weekly for 20 weeks.
bValues represent average number of tumors per animals.
cB(a)P dose for experiment 2 was 100 mg/kg.
*Significantly different from control value (p < 0.01) as determined by Fisher's exact test (lung adenoma) and the Gehan-Wilcoxon test (skin
papilloma).
tSignificantly different from control value (p < 0.001) as determined by Fisher's exact test (lung adenoma) and Gehan-Wilcoxon test (skin
papilloma).
tSignificantly different from control value (p < 0.05) as determined by Fisher's exact test (lung adenoma) and the Cox-type trend test (skin
papilloma).
used in the experiment 2 all increased the papilloma
count in the SENCAR strain. In experiment 3 in the
case of B(a)P, somewhat smaller responses were ob-
served. These responses could be partially accounted
for by the lower dose used in experiment 3. However,
decreased responses in the experiment 3 to EC and
FANFT appearto reflect variability in the model. ACR
produced a small but consistent response in both the
SENCAR and ICR strains. This response would ordi-
narilybe considered negative. However, concurrent ex-
periments at higher doses have clearly shown that ac-
rylamide is capable ofinitiating skin tumors in both the
SENCAR (11) and the ICR Swiss mouse (10). In the
ICR-Swiss mice, only EC and FANFT increased skin
tumor yields, but these yields were not significantly
different from those in the control groups.
Another experiment using the same dose ofTPA for
all strains (1 ,ug three times weekly) produced similar
lung responses to these chemicals (data not shown).
However, at this dose ofTPA, only the SENCAR skin
responded to the initiators.
In experiments 1 and 3 for all animals, lesions diag-
nosed as primary lung tumors by the Shimkin method
andallotherlunglesionsofquestionable diagnosisbased
on gross examination were evaluated microscopically
for confirmation, and final tumor counts were adjusted
based on these findings. In the ICR-Swiss, BALB/c,
and A/J strains, there was generally close diagnostic
correlation between the Shimkin gross interpretation
and the microscopic diagnosis. However, in the SEN-
CAR strain, the presence of a variety ofinflammatory
and proliferative lesions in the lungs greatly compro-
mised the diagnostic accuracy of the Shimkin method.
FIGURE 1. Alveolar bronchiolar adenoma. This photograph shows a
low magnification of a solid appearing, subpleural lung adenoma
typical ofstrain "A" tumors observed inmostofthetumor-bearing
SENCAR mice. (x50)
The morphologic features of various lung lesions ob-
served in the SENCAR strain are demonstrated in Fig-
ures 1-5. Typical subpleural primary lung adenomas
were frequently found in the SENCAR lungs in this
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FIGURE 2. Granulo,matous inflammation. This pulmonary inflam-
matory lesion is solid, subpleural in distribution, and had a gross
presentation very similar to that of the primary lung tumor in
Fig. 1. (x 80)
FIGURE 4. Alveolar bronchiolar adenomas. Many of the lung aden-
omas in the SENCAR strain were parenchymal tumors with an
airway distribution. These were small, less distinct, more loosely arranged tumors making them difficult to interpret by gross ob-
servation. ( x50)
study(Fig. 1). Thelesionismorphologically solidintype
and on gross examination presents as a raised pale tan
circumscribed nodule. However, nonneoplastic lesions
in the SENCAR strain interfere with the accuracy of
the Shimkin method oflung adenoma counting because
they often appear grossly similar to primary tumors.
There lesions occur as chronic-active or granulomatous
FIGURE 3. Proliferative inflammation. This inflammatory change,
with an airway distribution, consisted of Type II lining cell hy-
perplasia andalveolarhistiocytosis. Itsgross appearance wasvery
similar to that oflungtumor shown in Fig. 4. This lesion appeared
to be treatment-related and toxic in origin. ( x50)
FIGURE 5. Metastatic squamous cell carcinoma. A number ofthese
malignant skin lesions in the SENCAR mouse combined study metastasized to the lung. This well circumscribed metastases ap- peared very similar grossly to the primary lung tumor shown in
Fig. 4. (x50)
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inflammation (Fig. 2) and consist of alveolar lining cell
hyperplasia, alveolar histiocytosis, and interstitial fi-
brosis withinfiltration ofinterstitial and alveolarspaces
by lymphocytes (Fig. 3). Lungtumor counting in SEN-
CAR mice is furthercomplicatedbythe size, depth, and
loose arrangement of many adenomas, which makes
them less easily defined on gross examination (Fig. 4),
and by the presence of metastatic squamous cell car-
cinomas (Fig. 5) that result from the carcinogenic re-
sponse in the skin.
Conclusion
This study confirms the findings of Slaga et al. (8)
that the SENCAR mouse is the most sensitive of the
four strains tested for use in the skin papilloma assay.
In addition, we have shown that the SENCAR strain
also responds to chemical carcinogens by developing
lungadenomas. However, the presence ofinflammatory
changes in the lungs that have a similar gross appear-
ance as that of primary tumors makes it necessary to
confirm microscopically all lunglesions in the SENCAR
mouse. Although these proliferative inflammatory le-
sions may be treatment related, it could not be deter-
mined whether they were induced by the carcinogens
used, Emulphor, or some other agent.
Although the A/J strain is the most sensitive in the
lung adenoma test, it was totally nonresponsive in the
skin to the chemicals tested. The BALB/c mice were
also negative for these chemicals in the skin and only
very marginally responsive in the lung with EC and
FANFT treatments. The carcinogenic activity of the
three chemicals tested in ICR-Swiss mice produced re-
sponses in both the lung and skin. However, the ICR-
Swiss mice were generally less responsive than the
SENCAR mice in both target organs.
It should be noted that the present study does not
assess the responsiveness of the lung in the classical
manner, that is, only one dose of carcinogen was ad-
ministered. Repeated dosing as advocated in the orig-
inal studies ofShimkin would increase the yield oflung
adenomas. For example, repeated oral or intraperito-
neal doses of 25 and 30 ,ug/kg, respectively, of ACR 3
times weekly for 8 weeks produced approximately 1.4
and 2.2tumors per animal, respectively, in recent stud-
ies (11).
Ideally, the application ofacombined bioassay should
use the responses of two target tissues to broaden the
number ofclasses ofchemical carcinogens that could be
detected with either assay alone. The present experi-
ments suggest that the SENCAR mouse does possess
this advantage. This was most dramatically illustrated
by the fact that DEN, generally found to be negative
in the mouse skin initiation/promotion assay, elicited a
positive response in the lung of the SENCAR strain
under the same experimental conditions. A similar, but
less effective argument can be made with respect to the
fact that the tumorigenicity of FANFT was demon-
strated inthe mouse skinassay (confirmingearlierstud-
ies in our laboratory) but did not produce a positive
response in the lung of any strain. However, the low-
level response in the skin to FANFT in experiment 1
was not as apparent in experiment 2. Finally, it must
be noted that the advantage gained by using a single
animal in these tests must be offset by the greater dif-
ficulty in scoring lung adenoma yields in strains other
than the A/J mouse. Within the context ofthe present
study, this difficulty seems unique to SENCAR mice.
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